Budesonide: a novel treatment for oral chronic graft versus host disease.
OBJECTIVE
This clinical trial aims to evaluate the efficacy of budesonide, a newly registered steroid with high potency and low bioavailability, for the treatment of chronic oral graft versus host disease (GVHD).


METHODS
Twelve patients with chronic resistant oral GVHD were treated with 3 mg budesonide/5 ml saline 2 to 3 times a day for up to 3 months. Oral manifestations were monitored, and mucosal response scored.


RESULTS
All patients responded positively to the mouthwash, and 7 of the 12 patients were scored as having "good" or "complete" recovery by both examiner and subject. An early response noted within the first 2 to 3 weeks of treatment was complemented by a probable cumulative effect seen during the first months of treatment.


CONCLUSIONS
Budesonide is suggested as an alternative treatment for chronic oral GVHD.
Elad
Sharon
S
Hospital Oral Medicine Department, Hadassah University Hospital and The Hebrew University-Hadassah School Of Dental Medicine, Jerusalem, Israel. eladhome@md.huji.ac.il
Or
Reuven
R
Garfunkel
Adi A
AA
Shapira
Michael Y
MY
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D019819:Budesonide / Q000627:therapeutic use*; D002908:Chronic Disease; D006086:Graft vs Host Disease / Q000188:drug therapy* / Q000209:etiology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D008875:Middle Aged; D009059:Mouth Diseases / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D009061:Mouth Mucosa / Q000276:immunology; D009067:Mouthwashes / Q000627:therapeutic use*
D000893:Anti-Inflammatory Agents; D009067:Mouthwashes; D019819:Budesonide